Cargando…

2197. Hepatitis B Reactivation in Patients with Malignancies Undergoing Treatment for Hepatitis C Infection with Direct-Acting Antivirals

BACKGROUND: Reactivation of hepatitis B virus (HBV) can occur in patients after cancer therapies. Direct-acting antivirals (DAAs) are the effective therapies for hepatitis C virus (HCV) infection, and HBV reactivation in HCV/HBV co-infected patients treated with DAAs has been reported. We analyzed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pritchard, Haley, Hwang, Jessica P, Torres, Harrys
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254464/ http://dx.doi.org/10.1093/ofid/ofy210.1851

Ejemplares similares

Salvage Therapy in Cancer Patients With Hepatitis C Infection Failing Direct-Acting Antivirals: A Prospective Study
por: Pritchard, Haley, et al.
Publicado: (2017)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

2227. Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients
por: Hosry, Jeff, et al.
Publicado: (2018)

2228. Late Viral Relapse After Direct-Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients
por: Angelidakis, Georgios, et al.
Publicado: (2018)

Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct‐acting antivirals—A prospective study
por: Pritchard, Haley, et al.
Publicado: (2019)

288. Hepatitis B Virus Reactivation in Patients with Hematologic Malignancies after Anticancer Therapy Which Included Ibrutinib
por: Malek, Alexandre, et al.
Publicado: (2019)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Direct-acting Antivirals Induce Lymphoproliferative Disease Response in HCV-infected Patients: A Prospective Case Series
por: Hosry, Jeff, et al.
Publicado: (2017)

Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy
por: Mahale, Parag, et al.
Publicado: (2015)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

294. Hepatitis C Virologic Response in Hepatitis B and C Coinfected Persons Treated with Directly Acting Antiviral Agents: Results from ERCHIVES
por: Butt, Adeel A, et al.
Publicado: (2019)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Barriers to Hepatitis C Treatment in HIV co-infected Patients in the Era of New Direct-Acting Antiviral Therapy
por: Deering, Caytlin, et al.
Publicado: (2017)

Racial/Ethnic and Socioeconomic Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus in an Insured Population
por: Marcus, Julia, et al.
Publicado: (2017)

2225. Acute Hepatitis C Virus Infections in HIV-Infected Persons in the Era of Direct-Acting Antiviral Therapy
por: Cartwright, Emily J, et al.
Publicado: (2018)

919. Rates of False-Positive Hepatitis B Surface Antigen Is Low in Cancer Patients
por: Klingen, Joseph, et al.
Publicado: (2021)

Sustained Virologic Response with Direct Acting Antivirals in HIV Coinfected Hepatitis C Patients and Its Effect on Liver Fibrosis
por: Lebron, Dora, et al.
Publicado: (2017)

2938. Hepatitis C Virus Care Continuum in the Direct-acting Antiviral Era within the US Veterans Health Administration
por: Varley, Cara D, et al.
Publicado: (2023)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

2226. Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection: A Prospective Case-Series
por: Hosry, Jeff, et al.
Publicado: (2018)

Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals
por: Lee, Shou-Wu, et al.
Publicado: (2018)

Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment
por: Romano, Ciro, et al.
Publicado: (2022)

2222. Impact of Sustained Virologic Response Achieved Through Newer Direct Acting Antivirals in Hepatitis C Infection on Diabetes Mellitus
por: Mada, Pradeep Kumar, et al.
Publicado: (2018)

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2019)

Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2017)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ll1c4933v7caasgchos78vdbk3